Context Therapeutics/ US21077P1084 /

12/1/2023 9:59:50 PM	Chg. +0.02	Volume	Bid-	Ask-	High	Low
0.90USD	+2.27%	99 Turnover: 89.14	-Bid Size: -	-Ask Size: -	0.91	0.90

Newsfile Corp 10/20/2022 Context Therapeutics to Participate in the ThinkEquity Conference

GlobeNewswire 3/23/2022 Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

GlobeNewswire 3/9/2022 Proactive news headlines including Bitcoin, Lifeist Wellness, Imperial Helium, Fabled Copper, Contex...

GlobeNewswire 3/9/2022 Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Associa...

GlobeNewswire 2/24/2022 Proactive news headlines including Thunderbird Entertainment, NorthWest Copper, East Side Games, Ame...

GlobeNewswire 2/23/2022 Proactive news headlines including TRACON Pharmaceuticals, Gratomic, Benchmark Metals, Potent Ventur...

GlobeNewswire 2/22/2022 Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum

GlobeNewswire 1/5/2022 Context Therapeutics® Strengthens Research & Development Team

GlobeNewswire 1/4/2022 Context Therapeutics® to Participate in Two January 2022 Investor Conferences

GlobeNewswire 12/10/2021 Proactive news headlines including Tesla, Great Atlantic Resources, American Battery Technology Comp...

GlobeNewswire 12/10/2021 Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio...

GlobeNewswire 12/7/2021 Proactive news headlines including BuzzFeed, Steppe Gold, Esports Entertainment Group, Sanatana Res...

GlobeNewswire 12/6/2021 Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement

GlobeNewswire 12/3/2021 Proactive news headlines including Elon Musk, Vuzix, Context Therapeutics and American Manganese

GlobeNewswire 12/2/2021 Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results

GlobeNewswire 12/2/2021 Context Therapeutics Inc. Announces $31.25 Million Private Placement

GlobeNewswire 11/19/2021 Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast...

GlobeNewswire 11/1/2021 Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and C...

GlobeNewswire 10/27/2021 Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial o...

GlobeNewswire 10/22/2021 Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Under...

GlobeNewswire 10/20/2021 Context Therapeutics® Announces Pricing of Initial Public Offering

GlobeNewswire 9/8/2021 VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary

GlobeNewswire 8/25/2021 Context Therapeutics® and Tyligand Bioscience Reach ONA-XR Manufacturing Optimization Milestone

GlobeNewswire 5/12/2021 Context Therapeutics® and Jefferson Health Announce First Patient Dosed in Phase 2 Trial of ONA-XR i...

GlobeNewswire 4/8/2021 Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6...